Xenogenix Semax Nasal Spray 10,000mcg / 10ml

10,000mcg total Semax

10ml nasal spray format

Approx. 90 total sprays

Convenient measured spray delivery

Premium Xenogenix packaging

Suitable for research and educational reference

Labelled reference amounts for initiate, intermediate, and advanced research protocols

Compact amber bottle to help protect contents from light exposure

Research-focused product in the cognitive / neurological peptide category

Research reference only — not medical advice.

The packaging provides the following reference amounts:

Initiate:

222mcg = 2 sprays

Intermediate:

444mcg = 4 sprays

Advanced:

900mcg = 8 sprays

Based on the bottle information, the product contains 10,000mcg in 10ml with approximately 90 total sprays. This works out to roughly 111mcg per spray, although spray volume can vary slightly depending on the pump and handling.

This product is supplied for research purposes only and should not be presented as a treatment, cure, or approved medicine. Any real-world use should only be considered under appropriate professional guidance.

Storage:

Once opened, keep refrigerated below 16°C. Protect from direct sunlight. Keep out of reach of children.

What is Semax?

Semax is a synthetic research peptide derived from an ACTH fragment. It has been studied mainly for cognitive, neurological, neuroprotective, and stress-response pathways.

Where did Semax originally come from?

Semax was developed through Soviet/Russian peptide research, with work linked to the Institute of Molecular Genetics of the Russian Academy of Sciences. It began appearing in scientific literature around the early 1990s and has continued to be researched in Russia and other post-Soviet scientific settings.

Is Semax legal or used medically anywhere?

Semax has been used as a prescription medicine in Russia and parts of Eastern Europe. It is not approved or registered as a medicine in many Western markets, including the United States, so its legal and regulatory status depends on the country.

How long has Semax been researched?

Semax has been researched for more than 30 years, with published scientific work dating back to the early 1990s. Much of the early and ongoing work has come from Russian and post-Soviet research groups.

What did Russian researchers study Semax for?

Research has explored Semax in relation to attention, memory, learning, neurological recovery, ischemic stroke, optic nerve conditions, stress response, inflammation, and neuroprotective pathways. These areas remain research-focused and should not be presented as guaranteed outcomes.

What is the format of this product?

This product is supplied as a 10ml nasal spray.

How strong is the bottle?

Each bottle contains 10,000mcg total Semax.

How many sprays are in the bottle?

The packaging states approximately 90 total sprays.

How much Semax is in each spray?

Based on 10,000mcg divided by 90 sprays, each spray is approximately 111mcg.

Can Semax be mixed with other peptides?

In research discussions, Semax is sometimes considered alongside other cognitive, recovery, or neurological research peptides. However, combinations should be approached carefully and only within properly controlled research or professional contexts.

How should the product be stored?

Keep away from children, protect from direct sunlight, and refrigerate once opened below 16°C.

1. Russian peptide-drug development and the history of Semax

Semax is discussed in Russian peptide-drug development literature as one of the well-known synthetic regulatory peptide medicines developed from natural peptide fragments. Russian researchers describe Semax as a hybrid peptide based on an ACTH fragment combined with Pro-Gly-Pro, designed to improve stability and support neurological research applications.

This is useful because it shows Semax is not simply a recent online nootropic trend. It comes from a longer Russian research tradition around synthetic peptide medicines and neuroactive regulatory peptides.

URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9030433/

2. Semax and Russian Alzheimer’s / cognitive research

A 2025 Russian-linked study published in Acta Naturae investigated Semax and a Semax derivative in a transgenic mouse model of Alzheimer’s-type pathology. The study reported that Semax improved certain cognitive-function measures in the animal model and reduced amyloid plaque load in brain tissue. The authors described Semax and related derivatives as promising for further development in neurodegenerative-disease research.

This should be presented carefully as animal-model research, not as proof of human treatment benefit. It does, however, support why Semax continues to attract attention in cognitive and neuroprotective research.

URL: https://actanaturae.ru/2075-8251/article/view/27808

3. Semax, brain-cell gene expression and neuroprotection

Russian researchers have studied how Semax affects gene expression in rat brain cortical cells under experimental ischemic conditions. The study explored how Semax may influence genes connected to inflammation, immune response, vascular processes, and neuroprotection.

This type of research is important because it looks beyond “focus” or “memory” claims and investigates possible molecular pathways that may explain why Semax has been studied in neurological-stress models.

URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/

4. Semax and optic nerve research in Russia

Russian clinical research has also explored Semax in optic nerve disease. One study described Semax as a “new Russian drug” and evaluated its therapeutic effect in optic nerve conditions, reporting protective effects on nervous tissue, especially in the acute stage of optic nerve disease.

This area of research is one reason Semax is often discussed in relation to neuroprotection and nerve-tissue recovery pathways. It should still be framed as historical/regional research and not as an approved claim for this product.

URL: https://europepmc.org/article/med/10741256

5. Semax and ischemic stroke research

Semax has been discussed in scientific reviews of neuroprotective peptides for ischemic stroke. A 2023 review noted that Semax has shown neuroprotective effects in stroke-related research models and highlighted its Pro-Gly-Pro component, which may improve metabolic resistance.

This supports the idea that Semax has been researched in serious neurological contexts, especially around ischemia, brain stress, and neuroprotection. However, this remains research information and should not be used as a treatment claim.

URL: https://www.mdpi.com/2073-4425/14/5/953

6. Semax structure and Russian regulatory context

Russian research describes Semax as a synthetic ACTH-fragment analogue without hormonal activity. It has been included in Russian medical and research discussions for neurological pathologies and stress-related conditions. The Russian research background is one of the reasons Semax is often positioned differently from newer, less-studied peptide compounds.

URL: https://actanaturae.ru/2075-8251/article/view/27808

Semax has one of the longer research histories among cognitive and neuroactive peptides, with much of the early and ongoing work coming from Russian and post-Soviet scientific groups. Research has explored its possible role in cognitive performance, neuroprotection, stress response, optic nerve health, ischemic injury models, and neurodegenerative-disease pathways.

This product is supplied for research purposes only. It is not registered as an approved medicine or treatment, and the research discussed above should not be interpreted as medical advice or as proof of guaranteed results.